EP2748328A4 - PEG-INTERFERON LAMBDA 1 CONJUGATES - Google Patents
PEG-INTERFERON LAMBDA 1 CONJUGATESInfo
- Publication number
- EP2748328A4 EP2748328A4 EP12825651.8A EP12825651A EP2748328A4 EP 2748328 A4 EP2748328 A4 EP 2748328A4 EP 12825651 A EP12825651 A EP 12825651A EP 2748328 A4 EP2748328 A4 EP 2748328A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- conjugates
- peg
- interferon lambda
- interferon
- lambda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940079322 interferon Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| VN201102222 | 2011-08-25 | ||
| PCT/US2012/027317 WO2013028233A1 (en) | 2011-08-25 | 2012-03-01 | Peg-interferon lambda 1 conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2748328A1 EP2748328A1 (en) | 2014-07-02 |
| EP2748328A4 true EP2748328A4 (en) | 2015-03-04 |
Family
ID=47746747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP12825651.8A Withdrawn EP2748328A4 (en) | 2011-08-25 | 2012-03-01 | PEG-INTERFERON LAMBDA 1 CONJUGATES |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2748328A4 (enExample) |
| JP (1) | JP2014525939A (enExample) |
| CN (1) | CN103228792A (enExample) |
| AU (1) | AU2012299423A1 (enExample) |
| BR (1) | BR112014004302A2 (enExample) |
| CA (1) | CA2846092A1 (enExample) |
| RU (1) | RU2014111179A (enExample) |
| WO (1) | WO2013028233A1 (enExample) |
| ZA (1) | ZA201401159B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2874592T3 (es) * | 2016-02-19 | 2021-11-05 | Eiger Biopharmaceuticals Inc | Tratamiento de la infección por el virus de la hepatitis delta con interferón lambda |
| ES3015227T3 (en) | 2017-03-16 | 2025-04-30 | Evangelos Andreakos | Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder |
| RU2678332C1 (ru) * | 2017-09-08 | 2019-01-28 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") | Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения |
| CN112245570A (zh) | 2019-07-22 | 2021-01-22 | 厦门特宝生物工程股份有限公司 | 一种基于干扰素的疾病治疗方法 |
| AU2022210179A1 (en) | 2021-01-21 | 2023-09-07 | Biosteed Gene Transformation Tech. Co., Ltd. | Interferon-based cancer treatment method, and pharmaceutical combination |
| KR20230157947A (ko) | 2021-01-21 | 2023-11-17 | 샤먼 아모이탑 바이오테크 컴퍼니 리미티드 | 암 재발 방지를 위한 방법 및 약제학적 조합 |
| CN120676955A (zh) | 2022-12-09 | 2025-09-19 | Dys免疫治疗公司 | 产生抗hiv特异性中和抗体和/或抗hiv细胞毒性t细胞的复合aids疫苗 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| CN1176137C (zh) * | 2002-01-15 | 2004-11-17 | 泛亚生物技术有限公司 | 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用 |
| CN1927388B (zh) * | 2004-09-10 | 2011-02-02 | 北京金迪克生物技术研究所 | 含有人干扰素的药物组合物 |
| AU2006255122B2 (en) * | 2005-06-03 | 2010-10-21 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| WO2007041713A1 (en) * | 2005-10-04 | 2007-04-12 | Zymogenetics, Inc. | Production and purification of il-29 |
| CN101002942B (zh) * | 2007-01-08 | 2010-07-21 | 湖南大学 | 一种peg化脂质体纳米颗粒 |
| AU2009255994B2 (en) * | 2008-06-05 | 2014-07-17 | Bristol-Myers Squibb Company | Use of pegylated Type III Interferons for the treatment of hepatitis C |
-
2012
- 2012-03-01 WO PCT/US2012/027317 patent/WO2013028233A1/en not_active Ceased
- 2012-03-01 CA CA2846092A patent/CA2846092A1/en not_active Abandoned
- 2012-03-01 EP EP12825651.8A patent/EP2748328A4/en not_active Withdrawn
- 2012-03-01 AU AU2012299423A patent/AU2012299423A1/en not_active Abandoned
- 2012-03-01 JP JP2014527142A patent/JP2014525939A/ja not_active Withdrawn
- 2012-03-01 RU RU2014111179/10A patent/RU2014111179A/ru not_active Application Discontinuation
- 2012-03-01 BR BR112014004302A patent/BR112014004302A2/pt not_active IP Right Cessation
- 2012-03-01 CN CN2012800033678A patent/CN103228792A/zh active Pending
-
2014
- 2014-02-14 ZA ZA2014/01159A patent/ZA201401159B/en unknown
Non-Patent Citations (3)
| Title |
|---|
| AHAD ET AL: "Interferon to PEG-Interferon: A Review", THE JOURNAL OFTEACHERS ASSOCIATIONRMC, RAJSHAHI, vol. 17, no. 2, 1 December 2004 (2004-12-01), XP002734715 * |
| MUIR ANDREW J ET AL: "Phase 1b Study of Pegylated Interferon Lambda 1 With or Without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection", HEPATOLOGY, vol. 52, no. 3, September 2010 (2010-09-01), pages 822 - 832, XP002734714, ISSN: 0270-9139 * |
| See also references of WO2013028233A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012299423A1 (en) | 2014-03-06 |
| WO2013028233A1 (en) | 2013-02-28 |
| RU2014111179A (ru) | 2015-09-27 |
| ZA201401159B (en) | 2015-04-29 |
| CA2846092A1 (en) | 2013-02-28 |
| CN103228792A (zh) | 2013-07-31 |
| JP2014525939A (ja) | 2014-10-02 |
| BR112014004302A2 (pt) | 2017-06-20 |
| EP2748328A1 (en) | 2014-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201401159B (en) | Peg-interferon lambda 1 conjugates | |
| FR2971446B3 (fr) | Coiff'rasoir | |
| GB201114560D0 (en) | Concept 46 | |
| GB201114549D0 (en) | Concept 29 | |
| GB201114503D0 (en) | Concept 54 | |
| GB201114489D0 (en) | Concept 12 12 | |
| GB201114487D0 (en) | Concept 16 | |
| GB201114486D0 (en) | Concept 6 | |
| GB201114480D0 (en) | Concept 9 | |
| GB201114511D0 (en) | Concept 7 | |
| GB201114478D0 (en) | Concept 11 | |
| GB201114545D0 (en) | Concept 21 | |
| GB201104317D0 (en) | Concept 61 | |
| GB201104316D0 (en) | Concept 60 | |
| GB201103885D0 (en) | Concept 58 | |
| GB201103884D0 (en) | Concept 59 | |
| GB201101156D0 (en) | Concept 57 | |
| GB201100371D0 (en) | Concept 15 | |
| GB201100366D0 (en) | Concept 12 12 | |
| GB201114517D0 (en) | Concept 15 | |
| GB201114522D0 (en) | Concept 32 | |
| GB201114523D0 (en) | Concept 33 | |
| GB201114525D0 (en) | Concept 3 | |
| GB201114519D0 (en) | Concept 31 | |
| GB201114536D0 (en) | Concept 39 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20140311 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20150203 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 11/00 20060101AFI20150123BHEP Ipc: C12P 21/04 20060101ALI20150123BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20151203 |